Sangamo Therapeutics Faces Insider Sell‑Off Storm as Executive Sales Hint at Uncertain Future
Insider sales surge at Sangamo Therapeutics, sparking investor caution amid shaky gene‑therapy prospects.
3 minutes to read
Sangamo Therapeutics Inc
Sangamo Executives Stick to RSU Vesting, No Market Sell-Offs—Shareholders See Commitment, Not Confidence Worry
Insightful insider RSU sales at Sangamo Therapeutics show top execs are staying invested, not liquidating—signaling confidence in its genetic‑therapy pipeline for long‑term investors.
4 minutes to read